TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07276581: A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

Sponsor: AstraZeneca · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 320 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07276581 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07276581 Rescue Dossier →